Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections

Seiichi Aonuma; Kotaro Oizumi; Akira Watanabe; Yoshihiro Honda; Yutaka Tokue; Naoto Kitamura; Satoru Shoji; Masakichi Motomiya; Kiyoshi Konno; Kosaku Nagai

doi:10.11250/chemotherapy1953.38.Supplement1_106

Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections

Seiichi Aonuma, Kotaro Oizumi, Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Naoto Kitamura, Satoru Shoji, Masakichi Motomiya, Kiyoshi Konno, Kosaku Nagai

Research output: Contribution to journal › Article › peer-review

Abstract

We examined the in vitro antimicrobial activity of cefetamet (CEMT), a metabolite of the orally absorbed cefetamet pivoxil (CEMT-PI), a newly developed cephem antibiotic, by the broth dilution methed using the MIC-2000 system. Minimum inhibitory concentrations (MICs) of CEMT against 120 clinical isolates were compared with those of cefixime (CFIX) and cefaclor (CCL). Against Staphylococcus aureus, CEMT was less active than CFIX and CCL, but against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens it was much more active than CCL, though less active than CFIX. Against Enterobacter cloacae it was as active as CFIX. Eight patients suffering from respiratory tract infections were given 500mg or 1, 000mg of CEMT-PI orally once a day for 3∼8 days. Clinical response was good in seven and fair in one patient Wooziness was observed in one patient.

Original language	English
Pages (from-to)	106-109
Number of pages	4
Journal	Chemotherapy
Volume	38
DOIs	https://doi.org/10.11250/chemotherapy1953.38.Supplement1_106
Publication status	Published - 1990 Jan 1

Keywords

CEMT-PI
Cefetamet pivoxil

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

Access to Document

10.11250/chemotherapy1953.38.Supplement1_106

Fingerprint Dive into the research topics of 'Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections'. Together they form a unique fingerprint.

Cite this

Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections. / Aonuma, Seiichi; Oizumi, Kotaro; Watanabe, Akira; Honda, Yoshihiro; Tokue, Yutaka; Kitamura, Naoto; Shoji, Satoru; Motomiya, Masakichi; Konno, Kiyoshi; Nagai, Kosaku.

In: Chemotherapy, Vol. 38, 01.01.1990, p. 106-109.

Research output: Contribution to journal › Article › peer-review

@article{eaa58a7e13f049ffad1cefbfa7ad5148,

title = "Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections",

abstract = "We examined the in vitro antimicrobial activity of cefetamet (CEMT), a metabolite of the orally absorbed cefetamet pivoxil (CEMT-PI), a newly developed cephem antibiotic, by the broth dilution methed using the MIC-2000 system. Minimum inhibitory concentrations (MICs) of CEMT against 120 clinical isolates were compared with those of cefixime (CFIX) and cefaclor (CCL). Against Staphylococcus aureus, CEMT was less active than CFIX and CCL, but against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens it was much more active than CCL, though less active than CFIX. Against Enterobacter cloacae it was as active as CFIX. Eight patients suffering from respiratory tract infections were given 500mg or 1, 000mg of CEMT-PI orally once a day for 3∼8 days. Clinical response was good in seven and fair in one patient Wooziness was observed in one patient.",

keywords = "CEMT-PI, Cefetamet pivoxil",

author = "Seiichi Aonuma and Kotaro Oizumi and Akira Watanabe and Yoshihiro Honda and Yutaka Tokue and Naoto Kitamura and Satoru Shoji and Masakichi Motomiya and Kiyoshi Konno and Kosaku Nagai",

year = "1990",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.38.Supplement1_106",

language = "English",

volume = "38",

pages = "106--109",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections

AU - Aonuma, Seiichi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Honda, Yoshihiro

AU - Tokue, Yutaka

AU - Kitamura, Naoto

AU - Shoji, Satoru

AU - Motomiya, Masakichi

AU - Konno, Kiyoshi

AU - Nagai, Kosaku

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We examined the in vitro antimicrobial activity of cefetamet (CEMT), a metabolite of the orally absorbed cefetamet pivoxil (CEMT-PI), a newly developed cephem antibiotic, by the broth dilution methed using the MIC-2000 system. Minimum inhibitory concentrations (MICs) of CEMT against 120 clinical isolates were compared with those of cefixime (CFIX) and cefaclor (CCL). Against Staphylococcus aureus, CEMT was less active than CFIX and CCL, but against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens it was much more active than CCL, though less active than CFIX. Against Enterobacter cloacae it was as active as CFIX. Eight patients suffering from respiratory tract infections were given 500mg or 1, 000mg of CEMT-PI orally once a day for 3∼8 days. Clinical response was good in seven and fair in one patient Wooziness was observed in one patient.

AB - We examined the in vitro antimicrobial activity of cefetamet (CEMT), a metabolite of the orally absorbed cefetamet pivoxil (CEMT-PI), a newly developed cephem antibiotic, by the broth dilution methed using the MIC-2000 system. Minimum inhibitory concentrations (MICs) of CEMT against 120 clinical isolates were compared with those of cefixime (CFIX) and cefaclor (CCL). Against Staphylococcus aureus, CEMT was less active than CFIX and CCL, but against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens it was much more active than CCL, though less active than CFIX. Against Enterobacter cloacae it was as active as CFIX. Eight patients suffering from respiratory tract infections were given 500mg or 1, 000mg of CEMT-PI orally once a day for 3∼8 days. Clinical response was good in seven and fair in one patient Wooziness was observed in one patient.

KW - CEMT-PI

KW - Cefetamet pivoxil

UR - http://www.scopus.com/inward/record.url?scp=0025609526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025609526&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement1_106

DO - 10.11250/chemotherapy1953.38.Supplement1_106

M3 - Article

AN - SCOPUS:0025609526

VL - 38

SP - 106

EP - 109

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -